ストックスクリーナーアプリを入手
0.1844
1.39%
-0.0026
アフターアワーズ：
.18
-0.0044
-2.39%
前日終値:
$0.187
開ける：
$0.1869
24時間の取引高:
1.48M
Relative Volume:
0.16
時価総額：
$6.58M
収益：
-
当期純損益:
$-18.35M
株価収益率:
-0.159
EPS:
-1.16
ネットキャッシュフロー:
$-19.20M
1週間 パフォーマンス:
-6.40%
1か月 パフォーマンス:
-7.75%
6か月 パフォーマンス:
-54.44%
1年 パフォーマンス:
-86.34%
1日の値動き範囲:
$0.1813
$0.1877
1週間の範囲:
$0.1776
$0.20
52週間の値動き範囲:
$0.1628
$1.50
Theriva Biologics Inc Stock (TOVX) Company Profile
名前
Theriva Biologics Inc
セクター
電話
301 417 4364
住所
9605 Medical Center Drive, Suite 270, Rockville
Compare TOVX vs VRTX, REGN, ARGX, ALNY, ONC
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TOVX
Theriva Biologics Inc
|
0.1844 | 6.67M | 0 | -18.35M | -19.20M | -1.16 |
|
VRTX
Vertex Pharmaceuticals Inc
|
460.82 | 121.40B | 12.07B | 3.95B | 3.19B | 15.33 |
|
REGN
Regeneron Pharmaceuticals Inc
|
764.93 | 83.25B | 14.34B | 4.50B | 3.77B | 41.56 |
|
ARGX
Argen X Se Adr
|
728.11 | 46.39B | 4.16B | 1.29B | 734.26M | 19.59 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
320.51 | 43.41B | 3.71B | 313.75M | 465.38M | 2.2571 |
|
ONC
Beone Medicines Ltd Adr
|
292.94 | 33.09B | 5.36B | 287.73M | 924.18M | 2.5229 |
Theriva Biologics Inc (TOVX) 最新ニュース
TOVX Should I Buy - Intellectia AI
TOVX SEC FilingsTHERIVA BIOLOGICS INC 10-K, 10-Q, 8-K Forms - Stock Titan
Theriva™ Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Stocktwits
Theriva™ Biologics Announces Upcoming Presentation of Data from VCN-01 Retinoblastoma Phase 1 Clinical Trial at APAO 2026 - Stocktwits
TOVX Technical Analysis & ETF Price Forecast - Intellectia AI
Is Theriva Biologics Inc. stock a top pick in earnings season2025 Fundamental Recap & Intraday High Probability Setup Alerts - mfd.ru
TOVX Theriva Biologics AMEX pre-market +12% Feb 20 2026: Most active - Meyka
$30M Revenue Rocket, Super Spiders, and Biotech Patent Blitz Launch Morning Momentum - GlobeNewswire Inc.
Aug Update: What are Theriva Biologics Incs technical support levelsJuly 2025 News Drivers & Stepwise Trade Execution Plans - baoquankhu1.vn
Theriva Biologics licenses Syn-020 to Rasayana Therapeutics for multiple indications - marketscreener.com
Theriva Biologics Licenses Syn-020 To Rasayana Therapeutics For Multiple Indications - TradingView
Theriva Biologics (TOVX) Licenses SYN-020 to Rasayana Therapeuti - GuruFocus
Theriva Licenses SYN-020, Refocuses on Cancer Pipeline - TipRanks
Theriva Biologics Inc (referred to as Theriva Biologics) has successfully received a $300,000 upfront payment at the time of signing the agreement. - Bitget
Theriva Biologics Licenses SYN-020 to Rasayana Therapeutics for Multiple Indications - Bitget
How Theriva Biologics Inc. stock reacts to Fed rate cutsWeekly Profit Recap & Daily Price Action Insights - mfd.ru
Published on: 2026-02-14 06:14:36 - mfd.ru
Theriva Biologics Faces Delay in Warrant Approval Meeting - The Globe and Mail
How Theriva Biologics Inc. stock correlates with oil marketsM&A Rumor & Comprehensive Market Scan Insights - mfd.ru
Will Theriva Biologics Inc. outperform its industry peersWeekly Stock Report & Low Drawdown Trading Strategies - mfd.ru
Theriva Biologics Reschedules Stockholder Meeting - TradingView
Theriva Biologics (NYSE: TOVX) to reschedule vote on 16.18M warrant shares - Stock Titan
Death Cross: Can Theriva Biologics Inc. grow without dilutionJuly 2025 Selloffs & Daily Entry Point Trade Alerts - mfd.ru
Published on: 2026-02-09 23:08:24 - mfd.ru
Analyst Downgrade: Why is Theriva Biologics Inc stock going downJuly 2025 Weekly Recap & Long-Term Safe Return Strategies - baoquankhu1.vn
Bond Watch: Is Theriva Biologics Inc. subject to activist investor interest2025 Breakouts & Breakdowns & Weekly Setup with High ROI Potential - baoquankhu1.vn
Theriva™ Biologics Announces Upcoming Presentation of Data - GlobeNewswire
Trial tests VCN-01 before eye removal in hard-to-treat retinoblastoma - Stock Titan
Street Watch: Is Theriva Biologics Inc showing insider buyingWeekly Market Report & Technical Entry and Exit Alerts - baoquankhu1.vn
Is Theriva Biologics Inc backed by strong institutional buyingJuly 2025 Outlook & Technical Entry and Exit Tips - baoquankhu1.vn
Theriva Biologics (NYSEAMERICAN:TOVX) Stock Price Down 4.9% – Time to Sell? - Defense World
Dow Update: Can Theriva Biologics Inc continue delivering strong returnsWeekly Trade Report & Free Expert Approved Momentum Trade Ideas - baoquankhu1.vn
Can Theriva Biologics Inc continue delivering strong returnsQuarterly Portfolio Summary & Long-Term Growth Plans - baoquankhu1.vn
Theriva Biologics advances VCN-01 toward Phase 3 trial - TipRanks
How Theriva Biologics Inc. stock performs in rate cut cyclesProfit Target & Consistent Growth Equity Picks - Улправда
How Theriva Biologics Inc. stock reacts to fiscal policiesPortfolio Return Summary & AI Forecasted Entry/Exit Points - Улправда
Will Theriva Biologics Inc. stock profit from fiscal stimulusJuly 2025 Institutional & Free Technical Pattern Based Buy Signals - Улправда
Can Theriva Biologics Inc. stock maintain operating margins2025 Trading Recap & Technical Analysis for Trade Confirmation - Улправда
Is Theriva Biologics Inc. stock undervalued vs historical averagesOil Prices & Risk Managed Investment Entry Signals - Улправда
Can Theriva Biologics Inc. stock deliver sustainable ROE2025 Technical Overview & Comprehensive Market Scan Insights - ulpravda.ru
Will Theriva Biologics Inc. stock benefit from green energy trends2026 world cup usa national team semifinals defensive leaders pressing system match prediction preview - ulpravda.ru
Why Theriva Biologics Inc. stock is favored by pension funds2026 world cup usa national team quarterfinals goalkeepers low block defense match prediction statistical analysis - Улправда
How Theriva Biologics Inc. stock benefits from strong dollar2026 world cup usa national team group stage playmakers possession football winner prediction insights - Улправда
Theriva Biologics Incto Schedule End-of-Ph - 富途牛牛
Sentiment Watch: Is Theriva Biologics Inc stock at risk of policy regulationJuly 2025 EndofMonth & Long Hold Capital Preservation Plans - Bộ Nội Vụ
Theriva Biologics receives EMA approval for VCN-01 Phase 3 trial - Intellectia AI
Theriva Biologics receives CHMP scientific advice on VCN-01 Phase 3 design - Yahoo Finance
Theriva Biologics gains EMA backing for VCN-01 phase 3 - MSN
Theriva receives EMA guidance for pancreatic cancer drug trial design By Investing.com - Investing.com Nigeria
Why Is Theriva Biologics Stock Gaining Monday? - Benzinga
Theriva Biologics stock soars after EMA backs Phase 3 trial design - Investing.com Nigeria
Theriva Biologics Inc (TOVX) 財務データ
収益
当期純利益
現金流量
EPS
3.69%
0.68%
大文字化:
|
ボリューム (24 時間):